MX2012000437A - Polimorfos cristalinos estables de la sal dipotasica de acido (s)-2-{2,4-diamono-quizolin-6-il)-etil]-benzoilamino}-4-metilen-p entanodioico. - Google Patents

Polimorfos cristalinos estables de la sal dipotasica de acido (s)-2-{2,4-diamono-quizolin-6-il)-etil]-benzoilamino}-4-metilen-p entanodioico.

Info

Publication number
MX2012000437A
MX2012000437A MX2012000437A MX2012000437A MX2012000437A MX 2012000437 A MX2012000437 A MX 2012000437A MX 2012000437 A MX2012000437 A MX 2012000437A MX 2012000437 A MX2012000437 A MX 2012000437A MX 2012000437 A MX2012000437 A MX 2012000437A
Authority
MX
Mexico
Prior art keywords
polymorphs
benzoylamino
ethyl
dipotassium salt
stable crystalline
Prior art date
Application number
MX2012000437A
Other languages
English (en)
Inventor
Karol Horvath
Harish K Pimplaskar
Mikhail Lebedev
Original Assignee
Chelsea Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chelsea Therapeutics Inc filed Critical Chelsea Therapeutics Inc
Publication of MX2012000437A publication Critical patent/MX2012000437A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención provee formas polimórficas cristalinas estables de compuestos antifolatos, particularmente la sal dipotásica del ácido (S)-2-{4-[2-(2,4-diamino-quinazolin-6-il)-eti l]-benzoilamino}-4-metilen-pentanodioico, y métodos de preparación de las mismas; los polimorfos pueden estar en forma de hidratos; la invención también provee composiciones farmacéuticas que comprenden los polimorfos y métodos de tratamiento usando los polimorfos; los polimorfos son útiles en el tratamiento de múltiples afecciones que incluyen proliferación celular anormal, enfermedades inflamatorias, asma y artritis, y los polimorfos se pueden administrar solos o en combinación con uno o más agentes activos adicionales.
MX2012000437A 2009-07-08 2010-07-07 Polimorfos cristalinos estables de la sal dipotasica de acido (s)-2-{2,4-diamono-quizolin-6-il)-etil]-benzoilamino}-4-metilen-p entanodioico. MX2012000437A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22388809P 2009-07-08 2009-07-08
PCT/US2010/041171 WO2011005832A1 (en) 2009-07-08 2010-07-07 Stable crystalline polymorphs of the dipotassium salt of (s) -2- {4- [2- (2, 4-diamin0-quinaz0lin-6-yl) -ethyl] -benzoylamino} -4-methylenξ-penta nedioic acid

Publications (1)

Publication Number Publication Date
MX2012000437A true MX2012000437A (es) 2012-02-21

Family

ID=42830215

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000437A MX2012000437A (es) 2009-07-08 2010-07-07 Polimorfos cristalinos estables de la sal dipotasica de acido (s)-2-{2,4-diamono-quizolin-6-il)-etil]-benzoilamino}-4-metilen-p entanodioico.

Country Status (7)

Country Link
US (1) US20110124650A1 (es)
EP (1) EP2451788A1 (es)
JP (1) JP2012532877A (es)
AU (1) AU2010270596A1 (es)
CA (1) CA2767257A1 (es)
MX (1) MX2012000437A (es)
WO (1) WO2011005832A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658652B2 (en) 2010-12-07 2014-02-25 Chelsea Therapeutics, Inc. Antifolate combinations

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818753A (en) * 1987-09-18 1989-04-04 Sri International Synthesis and method of use for 2, 4 diaminoquinazoline
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
US5028608A (en) * 1989-12-11 1991-07-02 The Trustees Of Princeton University N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5248775A (en) * 1989-12-11 1993-09-28 The Trustees Of Princeton University Pyrrolo(2,3-d)pyrimidines
US5073554A (en) * 1990-01-18 1991-12-17 Nair Madhavan G Two non-polyglutamatable antifolates
US4996207A (en) * 1990-01-18 1991-02-26 Nair Madhavan G Three new non-polyglutamatable deazaaminopterins
US5508281A (en) * 1991-04-08 1996-04-16 Duquesne University Of The Holy Ghost Derivatives of pyrido [2,3-d] and [3,2-d] pyrimidine and methods of using these derivatives
IL108630A0 (en) * 1993-02-18 1994-05-30 Fmc Corp Insecticidal substituted 2,4-diaminoquinazolines
US5550128A (en) 1994-09-09 1996-08-27 Nair; Madhavan G. Enantiomers of gamma methylene 10-deaza aminopterin and process for preparing the same
US5593999A (en) * 1995-06-07 1997-01-14 Nair; Madhavan G. Non-classical folate analogue inhibitors of glycinamide ribonucleotide formyltransferase (GARFT)
AU7904998A (en) * 1997-07-07 1999-02-08 Peptichemio Ag Pharmaceutical composition containing peptichemio
US5912251A (en) * 1998-01-17 1999-06-15 Nair; Madhavan G. Metabolically inert anti-inflammatory and anti-tumor antifolates
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
CN1223378C (zh) * 2000-05-02 2005-10-19 施万制药 含有糖肽抗生素和环糊精的药物组合物
HUP0402305A2 (hu) * 2000-11-28 2005-02-28 Genentech, Inc. LFA-1-antagonista vegyületek, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
KR100685917B1 (ko) * 2000-12-27 2007-02-22 엘지.필립스 엘시디 주식회사 전계발광소자 및 그 제조방법
US20030181635A1 (en) * 2002-03-22 2003-09-25 Harry Kochat Process for coupling amino acids to an antifolate scaffold
US20040092739A1 (en) * 2002-11-13 2004-05-13 Zejun Xiao Process for synthesizing antifolates
US7060825B2 (en) * 2003-07-25 2006-06-13 Bionumerik Pharmaceuticals, Inc. Process for synthesizing 6-quinazolinyl-ethyl-benzoyl and related antifolates
US7612071B2 (en) * 2004-03-12 2009-11-03 Syntrix Biosystems, Inc. Compositions and methods employing aminopterin
WO2006029385A2 (en) * 2004-09-08 2006-03-16 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
US7687473B2 (en) * 2005-01-07 2010-03-30 Health Research, Inc. 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism
BRPI0909198A2 (pt) 2008-04-07 2019-09-24 Chelsea Therapeutics Inc composto antifolato, composto, método para preparar um composto antifolato, composição farmacêutica, método para tratar

Also Published As

Publication number Publication date
AU2010270596A1 (en) 2012-02-02
EP2451788A1 (en) 2012-05-16
US20110124650A1 (en) 2011-05-26
WO2011005832A1 (en) 2011-01-13
JP2012532877A (ja) 2012-12-20
CA2767257A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
UA112425C2 (uk) ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ
IN2014DN09348A (es)
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
NZ600439A (en) Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
NZ594589A (en) 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents
MX2013004491A (es) Boronatos como inhibidores de arginasa.
WO2007087204A3 (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
PH12015500587A1 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
MX2009009590A (es) Aminopirimidinas utiles como inhibidores de proteinas cinasas.
MX2012000414A (es) Derivados piridin-4-ilo.
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
MX2010001535A (es) Derivados de acido azabifenilaminobenzoico como inhibidores de la dihidroorotato deshidrogenasa.
MX2010008583A (es) Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.
MX350862B (es) Acidos de piperidinil naftilacetico.
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
MX2014003408A (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1).
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2014005075A (es) Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
WO2010018112A3 (en) Monoaryl aminotetralines
IL202248A (en) Aster 4– (3-Methoxy-4-Chloro-Phenyl) Piprazine-1-Il of Acid 3– (Imidazol-2-Il) -Pyrazolo] 4,3– [b Pyridine – 1-Acetic, Methods of preparation and use in preparation of medicinal products
UA109867C2 (ru) Замещенные соединения пиразола как антагонисты рецепторов лизофосфатидной кислоты (lpar)
NZ596527A (en) Nitrile derivatives and their pharmaceutical use and compositions
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal